• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于模拟的美罗培南在不同患者群体和实验设计中的药代动力学/药效学指标评估。

Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.

作者信息

Kristoffersson Anders N, David-Pierson Pascale, Parrott Neil J, Kuhlmann Olaf, Lave Thierry, Friberg Lena E, Nielsen Elisabet I

机构信息

Department of Pharmaceutical Biosciences, Uppsala Universitet, Box 591, Uppsala, SE-751 24, Sweden.

F. Hoffmann-La Roche Ltd., Innovation Center Basel, Pharmaceuticals Sciences, Basel, Switzerland.

出版信息

Pharm Res. 2016 May;33(5):1115-25. doi: 10.1007/s11095-016-1856-x. Epub 2016 Jan 19.

DOI:10.1007/s11095-016-1856-x
PMID:26786016
Abstract

PURPOSE

Antibiotic dose predictions based on PK/PD indices rely on that the index type and magnitude is insensitive to the pharmacokinetics (PK), the dosing regimen, and bacterial susceptibility. In this work we perform simulations to challenge these assumptions for meropenem and Pseudomonas aeruginosa.

METHODS

A published murine dose fractionation study was replicated in silico. The sensitivity of the PK/PD index towards experimental design, drug susceptibility, uncertainty in MIC and different PK profiles was evaluated.

RESULTS

The previous murine study data were well replicated with fT > MIC selected as the best predictor. However, for increased dosing frequencies fAUC/MIC was found to be more predictive and the magnitude of the index was sensitive to drug susceptibility. With human PK fT > MIC and fAUC/MIC had similar predictive capacities with preference for fT > MIC when short t1/2 and fAUC/MIC when long t1/2.

CONCLUSIONS

A longitudinal PKPD model based on in vitro data successfully predicted a previous in vivo study of meropenem. The type and magnitude of the PK/PD index were sensitive to the experimental design, the MIC and the PK. Therefore, it may be preferable to perform simulations for dose selection based on an integrated PK-PKPD model rather than using a fixed PK/PD index target.

摘要

目的

基于药代动力学/药效学(PK/PD)指标的抗生素剂量预测依赖于该指标类型和大小对药代动力学(PK)、给药方案及细菌敏感性不敏感。在本研究中,我们进行模拟以验证针对美罗培南和铜绿假单胞菌的这些假设。

方法

在计算机上复制一项已发表的小鼠剂量分割研究。评估PK/PD指标对实验设计、药物敏感性、最低抑菌浓度(MIC)不确定性及不同PK曲线的敏感性。

结果

以fT>MIC作为最佳预测指标时,先前小鼠研究数据得到很好的复制。然而,对于增加给药频率的情况,发现fAUC/MIC更具预测性,且该指标大小对药物敏感性敏感。对于人类PK,fT>MIC和fAUC/MIC具有相似的预测能力,t1/2短时倾向于fT>MIC,t1/2长时倾向于fAUC/MIC。

结论

基于体外数据的纵向PKPD模型成功预测了先前美罗培南的体内研究。PK/PD指标的类型和大小对实验设计、MIC及PK敏感。因此,基于整合的PK-PKPD模型进行剂量选择模拟可能比使用固定的PK/PD指标目标更可取。

相似文献

1
Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.基于模拟的美罗培南在不同患者群体和实验设计中的药代动力学/药效学指标评估。
Pharm Res. 2016 May;33(5):1115-25. doi: 10.1007/s11095-016-1856-x. Epub 2016 Jan 19.
2
A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.基于体外杀菌时间数据的药代动力学-药效学(PKPD)模型可预测黏菌素的体内PK/PD指标。
J Antimicrob Chemother. 2016 Jul;71(7):1881-4. doi: 10.1093/jac/dkw057. Epub 2016 Mar 16.
3
Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.美罗培南在儿童重症感染患者中的药代动力学和药效学。
Int J Antimicrob Agents. 2016 Aug;48(2):151-7. doi: 10.1016/j.ijantimicag.2016.04.025. Epub 2016 May 31.
4
[Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].基于药代动力学和药效学理论对美罗培南、比阿培南和多利培南治疗铜绿假单胞菌感染的有效给药方案分析
Jpn J Antibiot. 2007 Dec;60(6):394-403.
5
Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.半机械 PKPD 模型预测的抗生素药代动力学/药效学(PK/PD)指标:迈向基于模型的剂量优化的一步。
Antimicrob Agents Chemother. 2011 Oct;55(10):4619-30. doi: 10.1128/AAC.00182-11. Epub 2011 Aug 1.
6
Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.在PK/PD模型中量化的多黏菌素和美罗培南对野生型和耐药型铜绿假单胞菌的动态相互作用。
J Antimicrob Chemother. 2016 May;71(5):1279-90. doi: 10.1093/jac/dkv488. Epub 2016 Feb 4.
7
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.用于小鼠感染模型体内杀菌效果的药代动力学-药效学建模与模拟
J Pharm Sci. 2008 Apr;97(4):1606-14. doi: 10.1002/jps.21062.
8
Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.多黏菌素肺部给药在小鼠肺部感染模型中对铜绿假单胞菌的药代动力学/药效学研究
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02025-16. Print 2017 Mar.
9
Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.高剂量美罗培南(每日6克)治疗耐美罗培南铜绿假单胞菌所致实验性小鼠肺炎的疗效
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.02056-16. Print 2017 Jan.
10
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.通过动态中空纤维感染模型评估危重症患者药代动力学改变对美罗培南抗菌效果的重大影响。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02642-16. Print 2017 May.

引用本文的文献

1
Simulation-based evaluation of the impact of dose fractionation study design on antibiotic PKPD analyses.基于模拟评估剂量分割研究设计对抗生素药代动力学-药效学分析的影响。
JAC Antimicrob Resist. 2025 Apr 11;7(2):dlaf057. doi: 10.1093/jacamr/dlaf057. eCollection 2025 Apr.
2
A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidime.基于模型的阿维巴坦与头孢他啶联合用药的药代动力学-药效学(PKPD)评价。
JAC Antimicrob Resist. 2025 Mar 11;7(2):dlaf036. doi: 10.1093/jacamr/dlaf036. eCollection 2025 Apr.
3
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics.

本文引用的文献

1
Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.在PK/PD模型中量化的多黏菌素和美罗培南对野生型和耐药型铜绿假单胞菌的动态相互作用。
J Antimicrob Chemother. 2016 May;71(5):1279-90. doi: 10.1093/jac/dkv488. Epub 2016 Feb 4.
2
Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?β-内酰胺类抗生素的治疗药物监测:证据是什么,我们应该将其用于哪些患者?
J Antimicrob Chemother. 2015 Dec;70(12):3178-83. doi: 10.1093/jac/dkv201. Epub 2015 Jul 17.
3
A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.
在药代动力学/药效学(PK/PD)模拟中,并非总是需要从协变量分布中进行抽样:以抗生素为例进行说明。
J Pharmacokinet Pharmacodyn. 2025 Mar 4;52(2):19. doi: 10.1007/s10928-025-09967-6.
4
In vivo pharmacokinetic and pharmacodynamic study and cutoff of florfenicol against Riemerella anatipestifer in ducks.氟苯尼考对鸭疫里默氏菌的体内药代动力学和药效学研究及临界值
Poult Sci. 2025 Jan;104(1):104635. doi: 10.1016/j.psj.2024.104635. Epub 2024 Dec 4.
5
Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus.基于模型的阿法比星对金黄色葡萄球菌活性的体外实验结果到体内实验的转化
J Antimicrob Chemother. 2024 Dec 2;79(12):3150-3159. doi: 10.1093/jac/dkae334.
6
Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer's Perspective.新型抗生素研发中的转化药代动力学/药效学——药物开发者视角
Antibiotics (Basel). 2024 Jan 11;13(1):72. doi: 10.3390/antibiotics13010072.
7
Multistate modeling for survival analysis in critically ill patients treated with meropenem.多州建模分析美罗培南治疗危重症患者的生存情况。
CPT Pharmacometrics Syst Pharmacol. 2024 Feb;13(2):222-233. doi: 10.1002/psp4.13072. Epub 2023 Nov 7.
8
PK-PD integration of enrofloxacin and cefquinome alone and in combination against using an dynamic model.恩诺沙星和头孢喹肟单独及联合使用时基于动态模型的药代动力学-药效学整合研究(针对[此处原文缺失相关内容])
Front Pharmacol. 2023 Oct 6;14:1226936. doi: 10.3389/fphar.2023.1226936. eCollection 2023.
9
Concentrations of Co-Administered Meropenem and Vancomycin in Spinal Tissues Relevant for the Treatment of Pyogenic Spondylodiscitis-An Experimental Microdialysis Study.与化脓性脊椎椎间盘炎治疗相关的脊髓组织中联合使用美罗培南和万古霉素的浓度——一项实验性微透析研究
Antibiotics (Basel). 2023 May 14;12(5):907. doi: 10.3390/antibiotics12050907.
10
Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling.危重心脏病患者接受静脉-动脉体外膜肺氧合治疗时美罗培南的剂量优化:药代动力学/药效学建模
J Clin Med. 2022 Nov 8;11(22):6621. doi: 10.3390/jcm11226621.
一项关于药代动力学/药效学(PK/PD)指数图的提议,用于从抗生素的传统指数(AUC/MIC、Cmax/MIC和TAM)中选择最佳PK/PD指数。
Drug Metab Pharmacokinet. 2014;29(6):455-62. doi: 10.2133/dmpk.DMPK-14-RG-013. Epub 2014 Jul 8.
4
A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.建立了一个药代动力学/药效学模型,用于评估多黏菌素对铜绿假单胞菌的体外作用,并对模拟细菌杀灭中的群体药代动力学变异性进行评估。
J Antimicrob Chemother. 2014 May;69(5):1350-61. doi: 10.1093/jac/dkt520. Epub 2014 Jan 27.
5
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?DALI 研究:确定重症监护病房患者的抗生素水平:目前的β-内酰胺类抗生素剂量是否足以满足重症患者的需求?
Clin Infect Dis. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14.
6
Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs.抗菌药物的药代动力学-药效学建模。
Pharmacol Rev. 2013 Jun 26;65(3):1053-90. doi: 10.1124/pr.111.005769. Print 2013 Jul.
7
Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.多粘菌素甲磺酸盐负荷剂量在危重症患者中的应用:群体药代动力学、蛋白结合率及杀菌预测。
Antimicrob Agents Chemother. 2012 Aug;56(8):4241-9. doi: 10.1128/AAC.06426-11. Epub 2012 May 21.
8
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach.药代动力学/药效学在设定临床 MIC 折点中的作用:EUCAST 方法。
Clin Microbiol Infect. 2012 Mar;18(3):E37-45. doi: 10.1111/j.1469-0691.2011.03752.x. Epub 2012 Jan 20.
9
Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.庆大霉素药代动力学-药效学模型及其在新生儿中的预测剂量方案的适应性耐药性。
Antimicrob Agents Chemother. 2012 Jan;56(1):179-88. doi: 10.1128/AAC.00694-11. Epub 2011 Oct 28.
10
Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics.重新审视β-内酰胺类药物——PK/PD 改善了老抗生素的给药方案。
Curr Opin Pharmacol. 2011 Oct;11(5):470-6. doi: 10.1016/j.coph.2011.07.006. Epub 2011 Aug 19.